Dermatomyositis Associated with Multiple Myeloma and Amyloidosis – a Case Report

Česká verzia

Authors: Z. Ambler
Authors place of work: Neurologická klinika LF UK a FN Plzeň
Published in the journal: Cesk Slov Neurol N 2009; 72/105(1): 65-67
Category: Case Report

Summary

The article describes a case report of a female patient with paraneoplastic dermatomyositis which was associated with a multiple myeloma and amyloidosis. The most common types and incidence of malignancies associated with dermatomyositis or polymyositis are mentioned in the discussion section of the article.

Key words:
dermatomyositis – polymyositis – paraneoplastic syndromes – multiple myeloma – AL amyloidosis

Zdroje

1. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007; 2: 22.

2. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6(1): 9–13.

3. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25(2): 234–239.

4. Ponyi A, Constantin T, Garami M, András C, Tállai B,Váncsa A et al. Cancer associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64–71.

5. Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002; 41(11): 729–734.

6. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population based study. Lancet 2001; 357(9250): 96–100.

7. Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow up implications: a Scottish population based cohort study. Br J Cancer 2001; 85(1): 41–45.

8. Chakraverty R, Rabin N, Peggs K, Robinson S, Duncan JR, Yong K. Dermatomyositis and sarcoid like reaction associated with multiple myeloma treated effectively by high dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27(11): 1215–1217.

9. Borgia F, Vaccaró M, Guarneri F, Cannavó SP, Guarneri B. Dermatomyositis associated with IgG myeloma. Br J Dermatol 2001; 144(1): 200–201.

10. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G,Connors LH et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 2007; 56(11): 3858–3868.

11. Ambler Z. Neurologické projevy u mnohočetného myelomu. Neurol pro praxi 2008; 9(6): 300–304.

12. Sanchorawala V. Light chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006; 1(6): 1331–1334.

13. Müller AM, Geibel A, Neumann HP, Kühnemund A, Schmitt-Gräff A, Böhm J et al. Primary (AL) amyloidosis in plasma cell disorders. Oncologist 2006; 11(7): 824–830.

14. Zilko PJ, Dawkins RL. Amyloidosis associated with dermatomyositis and features of multiple myeloma: the progression of amyloidosis associated with corticosteroid and cytotoxic drug therapy. Am J Med 1975; 59(3): 448–452.